| Today’s Big NewsOct 24, 2023 |
|
Wednesday, November 1, 2023 | 1pm ET / 10am PT Join us to hear about a new, fully integrated and interoperable solution for Health at Home (Remote Care Delivery), with key insights on the journey from idea to market. You'll learn about EMR integration, managing data at scale, best practices on accelerating startup innovation, and much more. Register today! 
|
|
| By Kevin Dunleavy In the biopharma industry, post-merger layoffs are often a question of when and how many. In the case of Amgen’s $27.8 billion buyout of Horizon, they came quickly. Around 350 former Horizon employees are being told this week that their positions will be eliminated. |
|
|
|
By Andrea Park After spending the better part of the last three decades at Johnson & Johnson, Ashley McEvoy, worldwide chair of its medtech franchises, is charting a new course. |
By Gabrielle Masson AstraZeneca, home of cancer blockbusters like Tagrisso and Daiichi Sankyo-partnered Enhertu, is elevating its portfolio to create a “2.0” cancer pipeline, sharing a peek at data from three bispecific antibody candidates at this year's ESMO. |
By Zoey Becker The Centers for Disease Control and Prevention (CDC) recommends prioritizing available 100mg doses for babies at the highest risk of severe infection. Meanwhile, Sanofi and AstraZeneca are working to boosting supply. |
By Conor Hale Carl Icahn’s proxy battle against Illumina led to the replacement of its chairman and the resignation of its CEO. Now, the activist investor is going after the rest of the board. |
By Annalee Armstrong Eli Lilly’s Jacob Van Naarden thinks his peers’ rush to snap up every antibody-drug conjugate out there may be a little overblown. It bought in anyway. |
By Kevin Dunleavy On the market for two decades, AstraZeneca’s nasal spray flu vaccine, FluMist, may become available for self-administration as soon as next year. The FDA has accepted AZ’s supplemental biologics license application (sBLA) for self-administered FluMist Qudrivalent. The company expects a decision in the first quarter of next year and is making plans to launch the treatment in the 2024-2025 flu season. |
By Andrea Park The second quarter of this year marked the first time in over a year that Philips reported a positive net income, and—for now, at least—it’s staying there. |
By Max Bayer Aiolos Bio is sprinting out of stealth with nearly $250 million to help advance a phase 2-ready severe asthma med. The drug was acquired from Chinese biotech Jiangsu Hengrui Pharmaceuticals for an undisclosed amount. |
By Fraiser Kansteiner Mirati Therapeutics was long rumored to be the target of a Big Pharma buyout before Bristol Myers Squibb put up $5.8 billion for the California-based cancer drug developer in early October. Now, Mirati has revealed the tortuous bargaining process that led up to the deal. |
By Conor Hale GE HealthCare announced its recently greenlit image-guided therapy system would be compatible with Boston Scientific's guidance system for coronary procedures. |
By Max Bayer OrbiMed, one of the biggest global financers of private and public biopharmas, has brought in $4.3 billion to shower on new startups in the coming years. |
By Zoey Becker LianBio originally held the med's Asia commercialization rights under a 2020 collaboration with MyoKardia, which was later bought by Bristol Myers. Now, BMS is ponying up for those rights. |
By Nick Paul Taylor BrainStorm Cell Therapeutics has responded to its failure to win approval in the time-honored fashion. Yet, while the decision to lay off 30% of its staff is classical, the biotech’s reasoning is unusual. Rather than hunker down, BrainStorm is framing the action as a way to accelerate its journey back to the FDA. |
Fierce podcasts Don’t miss an episode |
| In this episode of "The Top Line," Fierce's Fraiser Kansteiner engages in a conversation with Alexander Scott, senior vice president of integrity at Eisai, to discuss the full approval of Leqembi and what it means for Eisai and, most importantly, for Alzheimer's patients. |
|
|---|
|
|
eBook Emulate in vivo biology with next-generation in vitro technology. Sponsored by: Emulate |
Whitepaper Uncover the keys to efficient bioprocessing, including how outsourcing quality management can reduce risk, save time and money, and expedite biologics development. Sponsored by: Thermo Scientific™ Production Chemicals and Services |
Whitepaper From trial site feasibility and patient populations to data analysis, generative AI has the potential to revolutionize drug discovery and clinical trial recruitment at both the therapeutic area and indication level. Sponsored by: H1 |
Whitepaper Accelerate drug discovery with high-performance computing (HPC) powered by the cloud Sponsored By: AWS, NVIDIA, and Rescale |
Whitepaper Uncover the keys to efficient bioprocessing, including how outsourcing quality management can reduce risk, save time and money, and expedite biologics development. Sponsored by: Thermo Scientific™ Production Chemicals and Services |
Webinar Embark on an in-depth journey through the pivotal Make-Test-Decide Workflow, where collaboration and data-driven decisions play a paramount role in the intricate landscape of drug discovery. Watch now to learn how cloud implementation fosters accessibility and collaboration, revolutionizing research across locations and companies. Sponsored by: Revvity Signals |
Whitepaper Economic and regulatory factors are making biopharma supply chains more complex in the EU. This paper explores strategies that biopharma companies can use to better manage complexity, cost, and risk. Presented by: AIM, the supply chain leader for life science entrants and midsize life science companies |
Whitepaper From Assay Development Through Large Molecule Development. Streamline your R&D workflows and gain valuable insights with our Biology Solutions Brochure. Download now to discover how to control your laboratory workflows across various assay techniques, modalities, and data types. Sponsored by: Revvity Signals |
| Edison Ballroom, New York City |
|
|
| |
|
